Free Trial

Stryker Co. (NYSE:SYK) Shares Acquired by Global Retirement Partners LLC

Stryker logo with Medical background

Global Retirement Partners LLC increased its stake in Stryker Co. (NYSE:SYK - Free Report) by 14.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,052 shares of the medical technology company's stock after buying an additional 869 shares during the period. Global Retirement Partners LLC's holdings in Stryker were worth $2,539,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Dunhill Financial LLC increased its position in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after buying an additional 37 shares in the last quarter. Darwin Wealth Management LLC bought a new position in shares of Stryker in the third quarter worth about $36,000. Activest Wealth Management purchased a new stake in Stryker during the 4th quarter valued at approximately $36,000. Crews Bank & Trust purchased a new stake in Stryker during the fourth quarter valued at $39,000. Finally, Hara Capital LLC purchased a new position in shares of Stryker during the 3rd quarter worth about $42,000. Hedge funds and other institutional investors own 77.09% of the company's stock.

Insiders Place Their Bets

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on SYK shares. JPMorgan Chase & Co. raised their price target on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Citigroup boosted their target price on shares of Stryker from $411.00 to $450.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Canaccord Genuity Group lifted their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Royal Bank of Canada upped their target price on shares of Stryker from $425.00 to $435.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 29th. Finally, The Goldman Sachs Group boosted their price target on Stryker from $384.00 to $427.00 and gave the company a "neutral" rating in a report on Thursday, January 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and a consensus target price of $420.68.

Check Out Our Latest Stock Analysis on SYK

Stryker Stock Down 1.0 %

Shares of SYK traded down $3.82 during mid-day trading on Friday, hitting $382.59. 1,268,413 shares of the company traded hands, compared to its average volume of 1,388,856. The business has a 50 day moving average of $377.92 and a 200 day moving average of $368.21. The company has a market capitalization of $145.99 billion, a PE ratio of 49.30, a price-to-earnings-growth ratio of 2.93 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the previous year, the company earned $3.46 earnings per share. Equities research analysts anticipate that Stryker Co. will post 13.49 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.88%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Stryker Company Profile

(Free Report)

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

Further Reading

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Should You Invest $1,000 in Stryker Right Now?

Before you consider Stryker, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.

While Stryker currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines